转移性胰腺癌的新兴治疗药物：聚焦早期临床试验。
Emerging agents for metastatic pancreatic cancer: spotlight on early phase clinical trials.
机构信息
Department of Oncology/Hematology, Kyungpook National University Hospital, School of Medicine, Kyungpook National University, Kyungpook National University, Daegu, Republic of Korea.
Department of Medicine, Royal Marsden Hospital, London, Surrey, UK.
出版信息
Expert Opin Investig Drugs. 2021 Nov;30(11):1089-1107. doi: 10.1080/13543784.2021.1995354. Epub 2021 Nov 2.
INTRODUCTION
Despite the recent development of new chemotherapeutic regimens and combination strategies, metastatic pancreatic cancer (mPC) still shows only a modest response to conventional cytotoxic agents. However, several novel therapeutic agents targeting the unique features of mPC are showing promise in clinical trials.
AREA COVERED
This article reviews the current state of development of new agents targeting various systems and molecular pathways. We searched PubMed and clinicaltrials.gov in September 2021 with a special focus on ongoing early phase clinical trials to identify the promising therapeutic strategies for mPC.
EXPERT OPINION
Extensive tumor heterogeneity, complex tumor microenvironment, genetic alterations of the oncogenic signaling pathways, metabolic dysregulation, and a low immunogenicity are hurdles for current treatment approaches. Ongoing research efforts strive to overcome these hurdles and are showing some promising early results.
简介
尽管最近开发了新的化疗方案和联合策略，转移性胰腺癌（mPC）对常规细胞毒药物的反应仍然只有适度。然而，几种针对 mPC 独特特征的新型治疗药物在临床试验中显示出希望。
涵盖领域
本文综述了靶向各种系统和分子途径的新型药物的最新发展状况。我们于 2021 年 9 月在 PubMed 和 clinicaltrials.gov 上进行了搜索，特别关注正在进行的早期临床试验，以确定 mPC 有前途的治疗策略。
专家意见
肿瘤异质性广泛、肿瘤微环境复杂、致癌信号通路的遗传改变、代谢失调和免疫原性低，这些都是当前治疗方法的障碍。正在进行的研究努力努力克服这些障碍，并显示出一些有希望的早期结果。
Zotero 插件